2-甲基-4-哌嗪喹啉 | 82241-22-3

• 物质功能分类: 医药中间体 - 杂环化合物 - 哌嗪类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 2-甲基-4-哌嗪喹啉
• 中文别名: 2-甲基-4-哌嗪基喹啉
• 英文名称: 2-methyl-4-(piperazin-1-yl)quinoline
• 英文别名: 2-Methyl-4-Piperazinoquinoline；2-methyl-4-piperazin-1-ylquinoline
• CAS: 82241-22-3
• 化学式: C₁₄H₁₇N₃
• mdl: MFCD01935745
• 分子量: 227.309
• InChiKey: XYBLCORUTWKJOI-UHFFFAOYSA-N

物化性质

• 熔点：
  101 °C
• 沸点：
  420.0±40.0 °C(Predicted)
• 密度：
  1.128±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.357
• 拓扑面积：
  28.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R20/21/22,R36/37/38
• 海关编码：
  2933990090
• 危险性防范说明：
  P280,P305+P351+P338,P310
• 危险性描述：
  H302,H315,H319,H332,H335

SDS

Name:	2-Methyl-4-piperazinoquinoline 97% Material Safety Data Sheet
Synonym:
CAS:	82241-22-3

Section 1 - Chemical Product MSDS Name:2-Methyl-4-piperazinoquinoline 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
82241-22-3	2-Methyl-4-piperazinoquinoline	97%	unlisted

Hazard Symbols: C
Risk Phrases: 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 82241-22-3: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: tan
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 100 - 101 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C14H17N3
Molecular Weight: 227

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Acid chlorides, oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide, acrid smoke and fumes.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 82241-22-3 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-Methyl-4-piperazinoquinoline - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: AMINES, SOLID, CORROSIVE, N.O.S.*
Hazard Class: 8
UN Number: 3259
Packing Group: III
IMO
Shipping Name: AMINES, SOLID, CORROSIVE, N.O.S.
Hazard Class: 8
UN Number: 3259
Packing Group: III
RID/ADR
Shipping Name: AMINES, SOLID, CORROSIVE, N.O.S.
Hazard Class: 8
UN Number: 3259
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 82241-22-3: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 82241-22-3 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 82241-22-3 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-甲基-4-哌嗪喹啉 在 三乙胺 、 间氯过氧苯甲酸 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 生成 (E)-1-[4-(2-methyl-1-oxidoquinolin-1-ium-4-yl)piperazin-1-yl]pent-2-en-1-one
  参考文献：
  名称：

  [EN] N-HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR THE TREATMENT OF PARASITIC DISEASES
  [FR] COMPOSÉS N-HÉTÉROARYLÉS AYANT UNE UNITÉ PONTANTE CYCLIQUE POUR LE TRAITEMENT DE MALADIES PARASITAIRES

  摘要：

  这项发明涉及某些N-杂环芳基化合物，通常用作药物，更具体地用作动物药物。该药物可以优选用于治疗蠕虫感染和寄生虫病的治疗，例如由蠕虫感染引起的寄生虫病。该发明还涉及利用这些化合物制备药物和治疗方法，包括将这些化合物用于需要治疗的动物的给药。此外，该发明还涉及N-杂环芳基化合物的制备。此外，该发明还涉及包含这些化合物的药物组合物和试剂盒。

  公开号：

  WO2012041872A1
• 作为产物：
  描述：

  4-氯喹哪啶 在 三氟乙酸 作用下， 以 丙二醇甲醚 、 二氯甲烷 为溶剂， 反应 4.75h， 生成 2-甲基-4-哌嗪喹啉
  参考文献：
  名称：

  [EN] N-HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR THE TREATMENT OF PARASITIC DISEASES
  [FR] COMPOSÉS N-HÉTÉROARYLÉS AYANT UNE UNITÉ PONTANTE CYCLIQUE POUR LE TRAITEMENT DE MALADIES PARASITAIRES

  摘要：

  这项发明涉及某些N-杂环芳基化合物，通常用作药物，更具体地用作动物药物。该药物可以优选用于治疗蠕虫感染和寄生虫病的治疗，例如由蠕虫感染引起的寄生虫病。该发明还涉及利用这些化合物制备药物和治疗方法，包括将这些化合物用于需要治疗的动物的给药。此外，该发明还涉及N-杂环芳基化合物的制备。此外，该发明还涉及包含这些化合物的药物组合物和试剂盒。

  公开号：

  WO2012041872A1

文献信息

• [EN] OGA INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS D'OGA
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2021123291A1

  公开（公告）日：2021-06-24

  The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations; or alpha synucleinopathies, in particular Parkinson's disease, dementia due to Parkinson's (or neurocognitive disorder due to Parkinson's disease), dementia with Lewy bodies, multiple system atrophy, or alpha synucleinopathy caused by Gaucher's disease.

  本发明涉及O-GlcNAc水解酶（OGA）抑制剂。该发明还涉及包含这类化合物的药物组合物，制备这类化合物和组合物的方法，以及利用这类化合物和组合物预防和治疗抑制OGA有益的疾病的用途，例如tau病变，特别是阿尔茨海默病或进行性上行性核瘫痪；以及伴有tau病理的神经退行性疾病，特别是由C9ORF72突变引起的肌萎缩侧索硬化或额颞叶痴呆；或α-突触核蛋白病，特别是帕金森病、帕金森病引起的痴呆（或由帕金森病引起的神经认知障碍）、带有Lewy小体的痴呆、多系统萎缩，或由高雪氏病引起的α-突触核蛋白病。
• [EN] CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME<br/>[FR] COMPOSÉS CARBAMATES ET LEUR PROCÉDÉ DE FABRICATION ET D'UTILISATION
  申请人：ABIDE THERAPEUTICS

  公开号：WO2013142307A1

  公开（公告）日：2013-09-26

  Provided herein are carbamate compounds which may be useful in the treatment of, for example, pain, solid tumors and/or obesity.

  本文提供的是可能在治疗疼痛、实体肿瘤和/或肥胖等方面有用的氨基甲酸酯化合物。
• [EN] CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME<br/>[FR] COMPOSÉS DE CARBAMATE ET LEUR PRÉPARATION ET UTILISATION
  申请人：ABIDE THERAPEUTICS

  公开号：WO2013103973A1

  公开（公告）日：2013-07-11

  This disclosure provides compounds and compositions which may be modulators of MAGL and/or ABHD6 and their use as medicinal agents, processes for their preparation, and pharmaceutical compositions that include disclosed compunds as at least one active agent. The disclosure also provides for method of treating a patient in need thereof, where the patient is suffering from indications such as pain, solid tumor cancer and/or obesity comprising administering a disclosed compound or composition.

  本公开提供了可能是MAGL和/或ABHD6的调节剂的化合物和组合物，以及它们作为药用剂的用途，它们的制备过程，以及包括所公开化合物作为至少一种活性剂的药物组合物。该公开还提供了一种治疗有需要的患者的方法，其中患者患有疼痛、实体肿瘤癌和/或肥胖等症状，包括给予公开的化合物或组合物。
• Phosphonium Salts as Pseudohalides: Regioselective Nickel‐Catalyzed Cross‐Coupling of Complex Pyridines and Diazines
  作者：Xuan Zhang、Andrew McNally

  DOI：10.1002/anie.201704948

  日期：2017.8.7

  traditional cross‐coupling methods. An alternative approach is presented where pyridines and diazines are converted into heteroaryl phosphonium salts and coupled with aryl boronic acids. Nickel catalysts are unique for selective heteroaryl transfer, and the reaction has a broad substrate scope that includes complex pharmaceuticals. Phosphonium ions also display orthogonal reactivity in cross‐couplings compared

  杂双芳基化合物是重要的药效团，很难通过传统的交叉偶联方法制备。提出了一种替代方法，其中将吡啶和二嗪转化为杂芳基phospho盐并与芳基硼酸偶联。镍催化剂对于选择性杂芳基转移是独特的，该反应具有广泛的底物范围，包括复杂的药物。与卤化物相比，离子在交叉偶联中也表现出正交反应性，从而实现化学选择性的钯和镍催化的偶联序列。
• [EN] COVALENT TARGETING OF E3 LIGASES<br/>[FR] CIBLAGE COVALENT DES LIGASES E3
  申请人：UNIV CALIFORNIA

  公开号：WO2020076996A1

  公开（公告）日：2020-04-16

  Disclosed herein, inter alia, are compositions and methods for targeting E3 ligases. In an aspect is a targeted protein degrader including 1) a targeted protein binder and 2) an E3 Ubiquitin ligase binder, wherein the E3 Ubiquitin ligase is human RNF4 or human RNF114. In an aspect is provided a pharmaceutical composition including a compound as described herein, including embodiments, and a pharmaceutically acceptable excipient.

  本公开的内容包括针对E3连接酶的组合物和方法。一个方面涉及一种靶向蛋白降解剂，包括1）靶向蛋白结合物和2）E3泛素连接酶结合物，其中E3泛素连接酶为人类RNF4或人类RNF114。另一方面提供了一种包括本文所述化合物的药物组合物，包括实施例和药用可接受的赋形剂。